Alpha 2.0
Login Register
» Articles » PMID: 36094846

Humoral and Cellular Responses to SARS-CoV-2 Vaccines Before and After Chimeric Antigen Receptor-modified T-cell Therapy

Overview
Journal Blood Adv
Specialty Hematology
Date 2022 Sep 12
PMID 36094846
Authors
Michael A Gonzalez
Atif M Bhatti
Kristin Fitzpatrick
Jim Boonyaratanakornkit
Meei-Li Huang
Victoria L Campbell
Jessica Hecht
Sarah Ibrahimi
Shera N Wanner
Damian J Green
David G Maloney
Jordan Gauthier
Andrew J Cowan
Alexander L Greninger
Elizabeth M Krantz
David M Koelle
Joshua A Hill
Affiliations
Soon will be listed here.
Citing Articles

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party....

Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrian N, Barba P Leukemia. 2024; 38(9):1985-1991.

PMID: 39043963 PMC: 11347385. DOI: 10.1038/s41375-024-02336-1.

INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.

McNerney K, Hsieh E, Shalabi H, Epperly R, Wolters P, Hill J Transplant Cell Ther. 2023; 30(1):38-55.

PMID: 37821079 PMC: 10842156. DOI: 10.1016/j.jtct.2023.10.006.

Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.

Infante M, Nemirovsky D, Devlin S, DeWolf S, Tamari R, Dahi P Transplant Cell Ther. 2023; 30(1):116.e1-116.e12.

PMID: 37806446 PMC: 11220618. DOI: 10.1016/j.jtct.2023.09.027.

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.

Aleissa M, Little J, Davey S, Saucier A, Zhou G, Gonzalez-Bocco I Transplant Cell Ther. 2023; 29(6):398.e1-398.e5.

PMID: 36906276 PMC: 9995387. DOI: 10.1016/j.jtct.2023.03.005.

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.

Haggenburg S, Hofsink Q, Rutten C, Nijhof I, Hazenberg M, Goorhuis A Semin Hematol. 2023; 59(4):192-197.

PMID: 36805887 PMC: 9674560. DOI: 10.1053/j.seminhematol.2022.11.001.

References
1.
Parvathaneni K, Torres-Rodriguez K, Meng W, Hwang W, Frey N, Naji A . SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments. JAMA Oncol. 2021; 8(1):164-167. PMC: 8603228. DOI: 10.1001/jamaoncol.2021.6030. View
2.
Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P . Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021; 138(14):1278-1281. PMC: 8332674. DOI: 10.1182/blood.2021012769. View
3.
Gastinne T, Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A . Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. Br J Haematol. 2021; 196(2):360-362. PMC: 8653317. DOI: 10.1111/bjh.17818. View
4.
Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y . Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. Transplant Cell Ther. 2021; 27(9):788-794. PMC: 8242200. DOI: 10.1016/j.jtct.2021.06.024. View
5.
Abid M, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M . Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022; 40(4):340-342. PMC: 8864440. DOI: 10.1016/j.ccell.2022.02.010. View